SELECT FROM MENU

Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immuno-therapies

Antibody Drug Conjugates

Antibody-Drug Conjugates

Immunotherapies in NSCLC

Immunotherapies in NSCLC

IO in early stage & combinations in late NSCLC LESS IS MORE – NEOADJUVANT IO ALONE IS UNDOUBTEDLY SUFFICIENT Patrick Forde EMBRACING ADDITIONAL ADJUVANT IO: A CRUCIAL AND NECESSARY ADD-ON Jordi Remon MAXIMIZING OUTCOMES: THE ROLE OF IO COMBINATIONS Solange Peters...

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates